"VPI Pharmaceuticals is focused on bringing best in class niche generic products to the Canadian market"
Steve Saviuk, President and CEO
VPI Pharmaceuticals is a Canadian pharmaceutical company specialized in bringing best in class niche generic products to customers in Canada. A wholly owned subsidiary of Valeo Pharma, based in Kirkland, Quebec, VPI Pharmaceuticals was founded in 2013 and began commercializing products that year.
Our focus is on bringing first or second to market generic products for the hospital and retail settings. With a flexible business model that includes development, acquisition or in-licensing products, VPI Pharmaceuticals has extensive experience in the commercialization of many different types of products from many different sources.
Our background includes the development of products such as Intrathecal VPI-Baclofen, Vancomycin (for injection) and VPI-Ethacrynate Sodium (for injection). These products were developed in-house from the ground up with external partners. We have also in-licensed products such as VPI-Benztropine (for injection), VPI-Piperacillin Tazobactam (for injection), and most recently VPI-Ondansetron ODT.
With an extensive pipeline and Business Development network, we are poised for rapid growth in the next 2 years.
VPI Pharmaceuticals is a fully integrated company with extensive in-house resources and expertise. Some of the capabilities that are housed in our Kirkland, Quebec operation include:
- Regulatory Affairs
- Quality Assurance
- Warehousing and distribution
- Customer Service